Fig. 1From: The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from ChinaSerum CA125 values in each group. Note: The CA125 level of the first follow-up was used as the reference value, and all data were converted to natural logarithm. CA125 follow-up data were obtained from 6 patient in the first-line maintenance treatment group and 16 patients in the exploratory therapy groupBack to article page